- organizations:Azura Ophthalmics
Pipeline
First patient enrolled in Azura's phase 3 MGD trial for AZR-MD-001
New study on selenium sulfide ointment follows positive phase 2 data supporting its ability to target the pathophysiology of MGD.Pipeline
Azura releases positive data from phase 2 trial of AZR-MD-001 for contact lens discomfort
Latest results on topical ointment support prior phase 2 findings unveiled at AAOPT.Pipeline
New 6-month data evaluates AZR-MD-001 for MGD
Presented at AAOPT, latest findings follow previous 3-month data evaluating the efficacy of two dosages.Pipeline